Revvity (RVTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates
Revvity (RVTY) came out with quarterly earnings of $1.7 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.42 per share a year ago.
Will Revvity Q4 Earnings Benefit From Early Signs of Demand Recovery?
RVTY's Q4 results are likely to benefit from early demand recovery signs in Life Sciences, but China Diagnostics headwinds may limit earnings upside.
Curious about Revvity (RVTY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Revvity (RVTY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Revvity (RVTY) Earnings Expected to Grow: Should You Buy?
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Revvity says it will exceed 2025 profit forecast range
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models
Revvity teams up with Eli Lilly to bring TuneLab AI models to Signals Xynthetica, aiming to unlock secure, federated drug discovery at scale.
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica
RVTY unveils Signals Xynthetica, an AI-augmented design platform that links predictive models with real lab data to speed discovery.
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
